Fact based stock research
GuiZhou SanLi Pharmaceutical (SHSE:603439)

CNE1000040B4



Due to the geopolitical instabilities, research on companies located in authoritarian regimes has been discontinued. Research at Obermatt is limited to companies in democracies as measured by The Economist Intelligence Unit Democracy Index.



GuiZhou SanLi Pharmaceutical stock research in summary

gz-sanli.com


There is no stock research analysis by the purely financial fact-based Obermatt method for: GuiZhou SanLi Pharmaceutical (SHSE:603439), Pharmaceuticals, China. Contact us if you would like research on this stock.


Latest Obermatt Ranks


Country China
Industry Pharmaceuticals
Index
Size class Small

February 24, 2022. Stock data may be delayed. Login to get the most recent research.

Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for GuiZhou SanLi Pharmaceutical from February 24, 2022.

We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.